

Moving beyond the 2018 international
Standards of Care for osteoporosis management

3rd INTERNATIONAL SYMPOSIUM

Muscle-Bone Interaction in Duchenne Muscular Dystrophy

NOVEMBER 7

MONDAY

Times are shown in UK time zone. Programme and speakers may be subject to change.

Hour	Title of talk	Speaker
17:00	Welcome, introduction	Jarod Wong (Glasgow, UK) Elizabeth Vroom (Amsterdam, NL)
The impact of steroids and DMD on musculoskeletal and endocrine outcomes Chairs: Pat Furlong & Jarod Wong		
17:05	Bone & endocrine morbidity in DMD with focus on the 2018 minimum international standards of care	David Weber (Philadelphia, USA)
17:30	Patient story: Fat embolism syndrome	
17:40	Steroid regimen and impact on muscle-bone & endocrine morbidity: Results from the FOR-DMD clinical trial	Michela Guglieri (Newcastle, UK) Leanne Ward (Ottawa, Canada)
18:05	High dose weekend only steroid regimen in DMD	Anne Connolly (Columbus, USA)
18:30	Patient story: Painful vertebral fracture	
18:40	Discussion	All, moderated by Jarod Wong
18:50	Break	

3rd International Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy

November 7 & 14

Times are shown in UK time zone. Programme and speakers may be subject to change.

Hour	Title of talk	Speaker
Implementing standards of care in the clinic with focus on bone/endocrine monitoring and management: Challenges, successes and lessons learnt Chairs: Alex Johnson & Michela Guglieri)		
18:55	World Duchenne Organization and its role in implementation of standards of care globally	Elizabeth Vroom (Netherlands, representing World Duchenne Organization)
19:00	The Parent Project Muscular Dystrophy certified centres approach in the USA	Rachel Schrader (USA, representing Parent Project Muscular Dystrophy)
19:05	The Duchenne Centre Netherlands approach in the Netherlands	Erik Niks (Netherlands, representing Duchenne Centre Netherlands)
19:10	The DMD Care UK approach in the UK NorthStar network and a national health system	Cathy Turner (UK, representing DMD Care UK)
19:15	Discussion	All, moderated by Michela Guglieri
Current bone monitoring and treatment strategies in DMD and the 2018 international Standards of Care Chairs: Elizabeth Vroom & Leanne Ward		
19:20	A walk-through of paediatric radiographic vertebral fracture evaluation	Khaldoun Koujok (Ontario, Canada)
19:45	An appraisal of the published literature on bone protective therapies in DMD recommended in the 2018 standards of care	Craig Munn (Brisbane, Australia)
20:10	Discussion	All, moderated by Leanne Ward
20:25	Summary and close	Jarod Wong (Glasgow, UK)

Moving beyond the 2018 international
Standards of Care for osteoporosis management

3rd INTERNATIONAL SYMPOSIUM

Muscle-Bone Interaction in Duchenne Muscular Dystrophy

NOVEMBER 14

MONDAY

Times are shown in UK time zone. Programme and speakers may be subject to change.

Hour	Title of talk	Speaker
17:00	Introduction	Jarod Wong (Glasgow, UK) Elizabeth Vroom (Amsterdam, NL)
17:05	Summary of DMD related abstracts from the International Conference on Children's Bone Health, Dublin 2022	Frank Rauch (Montreal, Canada)

Moving beyond the 2018 minimum international standards of care for bone management in DMD

Co-chairs: Leanne Ward & Michela Guglieri

17:15	Significant bone loss following cessation of ambulation in DMD: Is there a window of opportunity to introduce bone protective therapy?	Nicola Crabtree (Birmingham, UK)
17:35	The vertebral fracture cascade in DMD: Should the treatment threshold with bisphosphonates laid out in the 2018 minimum international standards of care be reconsidered?	Jarod Wong (Glasgow, UK)
17:55	Clinical predictors of vertebral fractures in DMD: Identifying patients for consideration of early treatment with osteoporosis agents	Kim Phung (Ottawa, Canada)

3rd International Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy

November 7 & 14

Times are shown in UK time zone. Programme and speakers may be subject to change.

Hour	Title of talk	Speaker
18:15	Oral bisphosphonate for mild vertebral fracture or declining bone density in DMD	Brenda Wong (USA)
18:35	The patient's perspective on the 2018 standards of care of osteoporosis management in DMD	Pat Furlong (Parent Project Muscular Dystrophy, USA)
18:45	Discussion	All, moderated by Leanne Ward & Michela Guglieri
19:00	Break	

New therapeutic approaches for osteoporosis in DMD

Co chairs: Jarod Wong & Michela Guglieri

19:05	RANKL inhibition and impact on musculoskeletal outcomes in an animal model of DMD	Soher Jayash (Edinburgh, UK)
19:25	The role of Denosumab for management of osteoporosis in DMD	Leanne Ward (Ottawa, Canada)
19:45	Vamorolone: Impact on skeletal muscle and bone outcome	Eric Hoffman (Binghamton, USA) Stefan Jackowski (Ottawa, Canada)
20:10	Discussion	All, moderated by Michela Guglieri & Jarod Wong
20:25	Summary and close	Jarod Wong (Glasgow, UK)